Projects funded by the NCN
Evaluation of anticancer potential of glutamine metabolism modulation in multiple myeloma sensitive and resistant to chemotherapy.
2016/21/N/NZ5/02585
Keywords:
multiple myeloma glutamine ASCT2 acquired resistance endoplasmic reticulum stress
Descriptors:
- NZ5_7: Human disease treatment
- NZ5_3: Pathogenesis of human diseases
- NZ3_1: Cell biology
Panel:
NZ5 - Human and animal noninfectious diseases: etiology, mechanisms, diagnosis and treatment of diseases, poisonings and injuries (without neurological diseases)
Host institution :
Uniwersytet Warszawski, Centrum Nowych Technologii Uniwersytetu Warszawskiego
woj. mazowieckie
Principal investigator (from the host institution):
Number of co-investigators in the project: 2
Call: PRELUDIUM 11 - announced on 2016-03-15
Amount awarded: 99 960 PLN
Project start date (Y-m-d): 2017-02-03
Project end date (Y-m-d): 2020-02-02
Project duration:: 36 months (the same as in the proposal)
Project status: Project settled
Project description
Download the project description in a pdf file
Note - project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
- Publication in academic press/journals (1)
- Inhibition of the ʟ-glutamine transporter ASCT2 sensitizes plasma cell myeloma cells to proteasome inhibitorsAuthors:Monika K.Prelowska, Dawid Mehlich, M. Talha Ugurlu, Hanna Kedzierska, Aleksandra Cwiek, Artur Kosnik, Klaudia Kaminska, Anna A. Marusiak, Dominika NowisAcademic press:Cancer Letters (rok: 2021, tom: 507, strony: 13-25), Wydawca: ElsevierStatus:PublishedDOI:10.1016/j.canlet.2021.02.020 - link to the publication